Generic Benchmarking: Brand Erosion at Patent Expiry

Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent expiry is increasing, driven by evolving payer initiatives to incentivize generic use.

Novartis AG: PharmaVitae Profile

This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Tuberculosis - Development pipeline shows signs of life

Tuberculosis is a major cause of illness and death worldwide, but despite 14.4 million prevalent cases, 9.2 million new cases and 1.7 million deaths in 2006, the small and rapidly declining burden of disease in the seven major markets has limited drug and vaccine development activities until recently.

Healthcare Technology Opportunities in the Electronic Health Record Market (Review Report)

Electronic health records (EHRs) will be the cornerstone of healthcare technology. The design, selection and implementation of EHRs, therefore, will be extremely important for healthcare institutions.

Generics Trends in the Seven Major Markets and Beyond

Based on generics use, the seven major markets may be divided into mature (the US, Germany and the UK) and immature (France, Italy, Spain and Japan) markets, both of which present different challenges, making the fast-growing, high-value emerging markets a tantalizing prospect. In addition to market expansion, acquisition and closer innovator ties represent key strategies for industry growth.

M&A trends in Pharma: Takeover activity in the last two and a half years

M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as favorable as desired. Current trends show the mega-mergers of the past are now a long gone strategy, as now companies are seeking to buy smaller companies for a smaller fee.

Pharma is divesting in order to grow

Pharmaceutical companies are now divesting non-core assets such as medical devices and manufacturing plants in an effort to cut costs and focus on core strategies, primarily drug development. However, while some Pharma companies are narrowing their focus, targeting specific disease areas for future growth, others are taking a broader approach in an effort to spread risk and return on investment.

Pharmaceutical Company Outlook to 2013

PharmaVitae universe Rx sales are forecast to expand at a 2007-13 CAGR of 2.4%, down 7.6 percentage points from 2001-07. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Strategic issues - Potential remains uncertain

Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.

Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011.

Stakeholder Analysis - A Panoramic View of the Emerging Biosimilars

Although Europe is leading the way, the biosimilar industry is very much in its infancy, with the perception of key decision makers critical to the initial rate of uptake. The opinion of key stakeholders, and the influence they wield, will therefore inform the strategy of both the branded and biosimilar contingents, in what is likely to become a battle to gain trust.

Trends in Pharmaceutical Portfolio Management - Strategies to maintain profitability despite adversity

With growing competition, Pharma companies are under increased pressure to deliver additional value for key stakeholders through their portfolios. Companies with comprehensive portfolios offering more to physicians, patients, payers and pharmacists will have the competitive edge.

Licensing to Win

As stakes get higher, and agreements get more challenging, what will it take for companies to win at licensing?

In an industry some accuse of stagnating, the ongoing rapid growth of licensing is a shining example of continuing clinical and business innovation and leadership. Licensing is already key to pharma’s success; last year, more than 350 deals with an announced value of over $25 billion helped make licensing responsible for more than half of major companies’ new product launches, and much of their pipelines.

Download  the full 28 pages report at Farmavita.Net - Download 

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

PHARMACEUTICALS AND BIOTECHNOLOGY IN CROATIA
Attractive Investment Opportunities

The pharmaceutical industry has a long tradition in Croatia and ‘know-how', promising successful future development of this and related industries. The most important pharmaceutical companies in Croatia are Pliva, Belupo, and Jadran Galenski Laboratorij. The pharmaceutical industry represents 4% of the total manufacturing industry employing 1.7% of the total employment in manufacturing in Croatia.

Complete  report (80 pages) is available for FREE downloat at Farmavta.Net Downloads Section.

Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000–2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.

Innovations in The Management of Diabetes: Next generation treatments and market dynamics

Diabetes has become the fifth leading cause of death across developed markets, and cases of the disease are forecast to grow by 7.1% across the globe by 2013. The market for innovative diabetes treatments will be driven by this projected rise in prevalence, together with the substantial unmet need for drugs that can effectively halt or reverse disease progression.

Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment

‘Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment’ explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area.